Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

15.08 -0.16 (-1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tonix Pharmaceuticals Holding Corp. - Common Stock

< Previous 1 2 3 4 Next >
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at AAPM 2025 PainConnect Meeting
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Fibromyalgia Drug Without Advisory Committee Review
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine for Mpox
Via Investor Brand Network
News headline image
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread
Via ACCESS Newswire
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4, Full-Year 2024 Financial Results, Highlights Key Developments
Via Investor Brand Network
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 BIO-Europe Spring Convention
Via Investor Brand Network
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances TNX-1500 to Address Organ Transplant Rejection
Via Investor Brand Network
News headline image
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target
Via ACCESS Newswire
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at Zacks SCR Life Sciences Virtual Forum
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures MCDC Grant for TNX-801 Smallpox and Mpox Vaccine Development
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at 2025 Virtual Investor Summit
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data on TNX-102 SL for Fibromyalgia
Via Investor Brand Network
Topics Emissions
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Preliminary 2024 Financial Results
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Positive Phase 1 Results for TNX-1500 in Transplant and Autoimmune Therapy
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO to Present at BIO CEO & Investor Conference
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Promotes Siobhan Fogarty to Chief Technical Officer
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces 1-for-100 Reverse Stock Split
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Appoints Gary Ainsworth as Vice President, Market Access
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at Neuroscience and Biotech Investor Conferences
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision on TNX-102 SL for Fibromyalgia
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Non-Opioid Fibromyalgia Treatment with FDA NDA Acceptance
Via Investor Brand Network
News headline image
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers
Via ACCESSWIRE
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awaits FDA Decision on New Fibromyalgia Treatment
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands Leadership Team to Support TNX-102 SL Launch
Via Investor Brand Network
InvestorkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at NobleCon20 Emerging Growth Conference
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) COO to Present at Winter 2024 Investor Summit
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Phase 3 Success for TNX-102 SL in Fibromyalgia Treatment
Via Investor Brand Network
Jessica Edgar Morris, COO of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), to Present at NobleCon20
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.